Ortec plans US trial for diabetic ulcer treatment
This article was originally published in Clinica
Executive Summary
Ortec International looks set to join the race to market a tissue-engineered treatment for diabetic ulcers in the US after submitting an application to the FDA to begin a clinical trial of its Composite Cultured Skin (CCS).